Remedium Lifecare Ltd
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
- Market Cap ₹ 80.3 Cr.
- Current Price ₹ 0.91
- High / Low ₹ 12.1 / 0.69
- Stock P/E 37.7
- Book Value ₹ 1.19
- Dividend Yield 0.00 %
- ROCE %
- ROE 4.85 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.76 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 1.13%
- Earnings include an other income of Rs.10.8 Cr.
- Company has high debtors of 695 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 405 | |
| 404 | |
| Operating Profit | 1 |
| OPM % | 0% |
| 11 | |
| Interest | 8 |
| Depreciation | 0 |
| Profit before tax | 4 |
| Tax % | 51% |
| 2 | |
| EPS in Rs | 0.02 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -47% |
| 1 Year: | -92% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Sep 2025 | |
|---|---|---|
| Equity Capital | 40 | 88 |
| Reserves | 4 | 17 |
| 1,141 | 1,088 | |
| 535 | 430 | |
| Total Liabilities | 1,720 | 1,623 |
| 0 | 6 | |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| 1,720 | 1,617 | |
| Total Assets | 1,720 | 1,623 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| -1,135 | |
| 0 | |
| 1,136 | |
| Net Cash Flow | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 695 |
| Inventory Days | 247 |
| Days Payable | 459 |
| Cash Conversion Cycle | 483 |
| Working Capital Days | 38 |
| ROCE % |
Documents
Announcements
-
Intimation Of Postponement And Rescheduling Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015
3h - Board meeting postponed to Feb 25, 2026 to approve Q3 and nine-month unaudited results; trading window closed.
-
Announcement under Regulation 30 (LODR)-Demise
4h - Company Secretary Kapil Goplani died on 13/01/2026; company informed 14/02/2026, replacement being appointed.
-
Board Meeting Intimation for Consider Un-Audited Financial Results/Statements (Standalone & Consolidated) Of The Company For The Third Quarter And Nine Months Ended December, 31, 2025
3 Feb - Board meeting on 14 Feb 2026 to consider Q3 and 9M unaudited results for Dec 31, 2025; trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
20 Jan - Submission of Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31.12.2025
-
Closure of Trading Window
22 Dec 2025 - Trading window closed 1 Jan 2026 until 48 hours after results for quarter and nine months ending 31 Dec 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
Company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets